Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to Buy at Wall Street Zen

Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also recently issued reports on the company. Craig Hallum raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Wells Fargo & Company raised their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research note on Monday, January 5th. Citigroup upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Finally, Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Ironwood Pharmaceuticals presently has an average rating of “Hold” and an average target price of $4.93.

Ironwood Pharmaceuticals Trading Down 3.6%

NASDAQ:IRWD opened at $3.49 on Friday. The company has a 50-day moving average of $4.32 and a 200-day moving average of $2.93. The firm has a market cap of $567.75 million, a price-to-earnings ratio of 26.85 and a beta of 0.24. Ironwood Pharmaceuticals has a twelve month low of $0.53 and a twelve month high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). Ironwood Pharmaceuticals had a negative return on equity of 13.72% and a net margin of 8.11%.The business had revenue of $47.71 million during the quarter, compared to the consensus estimate of $86.10 million. On average, research analysts forecast that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of IRWD. DGS Capital Management LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $35,000. Invesco Ltd. boosted its holdings in shares of Ironwood Pharmaceuticals by 22.6% during the fourth quarter. Invesco Ltd. now owns 449,219 shares of the biotechnology company’s stock worth $1,514,000 after purchasing an additional 82,687 shares during the period. Mercer Global Advisors Inc. ADV grew its position in Ironwood Pharmaceuticals by 7.8% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company’s stock valued at $259,000 after purchasing an additional 5,598 shares in the last quarter. XTX Topco Ltd increased its stake in Ironwood Pharmaceuticals by 290.4% in the 4th quarter. XTX Topco Ltd now owns 43,904 shares of the biotechnology company’s stock valued at $148,000 after buying an additional 32,657 shares during the period. Finally, Virtus Investment Advisers LLC purchased a new stake in Ironwood Pharmaceuticals in the 4th quarter worth approximately $250,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.